C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.170
+0.470 (17.41%)
At close: Mar 2, 2026, 4:00 PM EST
3.240
+0.070 (2.21%)
After-hours: Mar 2, 2026, 7:58 PM EST
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for C4 Therapeutics stock have an average target of 12.2, with a low estimate of 6.00 and a high estimate of 30. The average target predicts an increase of 284.86% from the current stock price of 3.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for C4 Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +120.82% | Feb 27, 2026 |
| Brookline Capital | Brookline Capital | Strong Buy Maintains $20 → $30 | Strong Buy | Maintains | $20 → $30 | +846.37% | Feb 23, 2026 |
| Barclays | Barclays | Buy Maintains $10 → $5 | Buy | Maintains | $10 → $5 | +57.73% | Dec 17, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 2, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +215.46% | Sep 23, 2025 |
Financial Forecast
Revenue This Year
22.98M
from 35.95M
Decreased by -36.08%
Revenue Next Year
23.41M
from 22.98M
Increased by 1.87%
EPS This Year
-1.37
from -1.42
EPS Next Year
-1.27
from -1.37
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 42.0M | 36.8M | |||
| Avg | 23.0M | 23.4M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 16.8% | 59.9% | |||
| Avg | -36.1% | 1.9% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.89 | -0.71 | |||
| Avg | -1.37 | -1.27 | |||
| Low | -1.87 | -1.76 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.